Suchergebnisse
Can Debottlenecking Drive Alto Ingredients' Next Growth Phase?
Alto Ingredients, Inc. ALTO is betting that a targeted operational upgrade can unlock meaningful production gains without the expense of building new capacity. In the first-quarter 2026 earnings
IonQ's Roadmap Execution Underpins Commercial Growth
IonQ’s IONQ commercialization thesis is supported by a roadmap built around defined technical milestones. The company targets an operational 256-qubit system in the fourth quarter of 2026.
During
AJG Strengthens Specialty Insurance Through Med James Acquisition
Arthur J. Gallagher & Co. AJG continues to strengthen its specialty insurance platform through targeted acquisitions, a strategy that has supported the company's long-term growth and expanded its
Resideo Technologies Targets Margin Growth as ADI Spin-Off Reshapes Strategy
Key Points
- Interested in Resideo Technologies, Inc.? Here are five stocks we like better.
- Resideo is positioning itself as a standalone building technologies company after the planned ADI
Wedbush Pounds the Table—Buy Sandisk Before August 5 Earnings
Key Points
- Interested in Sandisk Corporation? Here are five stocks we like better.
- Wedbush raised its Sandisk revenue, earnings, and price targets above consensus, forecasting nearly $9 billion
Can Fox (FOX) Climb 38.77% to Reach the Level Wall Street Analysts Expect?
Fox Corporation (FOX) closed the last trading session at $50.22, gaining 0.5% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall
Wall Street Analysts See a 43.91% Upside in ExlService Holdings (EXLS): Can the Stock Really Move This High?
ExlService Holdings (EXLS) closed the last trading session at $28.49, gaining 0.3% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by
Wall Street Analysts Predict a 94.13% Upside in FTC Solar (FTCI): Here's What You Should Know
FTC Solar (FTCI) closed the last trading session at $5.28, gaining 17.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall
Wall Street Analysts Believe Fox (FOXA) Could Rally 27.67%: Here's is How to Trade
Shares of Fox (FOXA) have gained 2.1% over the past four weeks to close the last trading session at $55.9, but there could still be a solid upside left in the stock if short-term price targets of
Wall Street Analysts Believe JD.com (JD) Could Rally 40.06%: Here's is How to Trade
JD.com, Inc. (JD) closed the last trading session at $28.88, gaining 0.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall
Wall Street Analysts Think Syndax (SNDX) Could Surge 70.38%: Read This Before Placing a Bet
Syndax Pharmaceuticals (SNDX) closed the last trading session at $22.89, gaining 23.9% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set
Ionis Begins Dosing in Phase I/II Dravet Syndrome Study
Ionis Pharmaceuticals IONS announced that it has dosed the first patient in the phase I/II ASCEND study, which is evaluating its investigational RNA-targeted medicine, ION337, for treating patients
Target (TGT) is a Top Dividend Stock Right Now: Should You Buy?
Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. But when you're an income investor, your
TGT vs. TJX: Which Stock Is the Better Value Option?
Investors interested in stocks from the Retail - Discount Stores sector have probably already heard of Target (TGT) and TJX (TJX). But which of these two stocks presents investors with the better
Can PayPal Beat Its Q2 FY26 Expectations Amid Tougher Trends?
PayPal Holdings, Inc. PYPL delivered a solid first-quarter 2026, but now the attention has shifted to whether management can meet its second-quarter targets. Revenues rose 7% to $8.35 billion or 5%
Biogen Backs Alzheimer’s Tau Drug for Phase 3 Despite Trial Miss
Key Points
- Interested in Biogen Inc.? Here are five stocks we like better.
- Biogen says its Phase 2 CELIA study of tau-targeting Alzheimer’s drug diranersen missed the main dose-response
Does Nvidia (NVDA) Have the Potential to Rally 42.85% as Wall Street Analysts Expect?
Nvidia (NVDA) closed the last trading session at $211.8, gaining 2.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street
Wall Street Analysts Predict a 28.47% Upside in StandardAero, Inc. (SARO): Here's What You Should Know
StandardAero, Inc. (SARO) closed the last trading session at $27.36, gaining 2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by
Does Paramount Resources (PRMRF) Have the Potential to Rally 25.22% as Wall Street Analysts Expect?
Paramount Resources (PRMRF) closed the last trading session at $20.5, gaining 1.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by
Wall Street Analysts See an 80.12% Upside in Q32 Bio (QTTB): Can the Stock Really Move This High?
Shares of Q32 Bio (QTTB) have gained 44.8% over the past four weeks to close the last trading session at $18.46, but there could still be a solid upside left in the stock if short-term price targets